Probability of overall death and cardiovascular death and probability of being ranked as the riskiest intervention for each treatment from the MTC meta-analysis
| Treatment | Overall death (N=42) | Cardiovascular death (N=31) | ||||||
| Probability of death, % (95% CrI) | Probability of being ranked as the riskiest intervention, % | Probability of death, % (95% CrI) | Probability of being ranked as the riskiest intervention, % | |||||
| Fixed effect | Random effects | Fixed effect | Random effects | Fixed effect | Random effects | Fixed effect | Random effects | |
| TIO-SMI | 8.26 (2.55 to 23.61) | 8.32 (2.51 to 24.46) | 96.94 | 94.61 | 3.63 (0.98 to 12.82) | 3.83 (0.90 to 15.63) | 98.34 | 89.49 |
| TIO-HH | 5.19 (1.64 to 15.16) | 5.18 (1.62 to 15.40) | 0.08 | 0.79 | 1.56 (0.47 to 4.98) | 1.79 (0.51 to 6.29) | 0.27 | 4.74 |
| LABA | 5.26 (1.65 to 15.38) | 5.34 (1.65 to 16.03) | 0.15 | 1.30 | 1.22 (0.37 to 4.00) | 1.40 (0.39 to 5.07) | 0.01 | 1.04 |
| LABA-ICS | 4.52 (1.41 to 13.45) | 4.50 (1.39 to 13.56) | 0.00 | 0.06 | 1.33 (0.40 to 4.32) | 1.29 (0.35 to 4.48) | 0.04 | 0.31 |
| ICS | 5.78 (1.82 to 16.73) | 5.52 (1.72 to 16.33) | 2.50 | 2.57 | 1.55 (0.47 to 5.05) | 1.70 (0.47 to 6.03) | 0.45 | 3.60 |
| PL | 5.62 (1.79 to 16.23) | 5.57 (1.77 to 16.26) | 0.33 | 0.67 | 1.78 (0.56 to 5.56) | 1.77 (0.55 to 5.49) | 0.91 | 0.82 |
‘N’ represents the number of trials reporting on each outcome.
CrI, credible interval ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; MTC, mixed treatment comparison; PL, placebo; TIO-HH, tiotropium dry powder delivered via HandiHaler; TIO-SMI, tiotropium solution delivered via Resipmat Soft Mist Inhaler.